The effects of caffeine on walking and balance in patients with multiple sclerosis

Determine the effect of caffeine on the ability to walk and balance in patients with multiple sclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017012332142N1

Enrollment

Registered

2017-03-27

Start date

2017-03-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Consumption of caffeine, the chemical composition: pure caffeine concentration: 100%, dose: 2.5 mg per kilogram of body weight on a daily basis (minimum dose), the frequency of use: on

Placebo

Consumption of caffeine, the chemical composition: pure caffeine concentration: 100%, dose: 2.5 mg per kilogram of body weight on a daily basis (minimum dose), the frequency of use: once a day, durati

Substance: folic acid in the form of capsules that you're going to throw Caffeine, the chemical composition: folic acid, concentration: 100%, dosage: One mg, the frequency of use: once a day, duration

Eligibility

Sex/Gender

All

Age

20 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age-related diseases in the range of 20-55; has no history of patients without a history of allergy to caffeine; aggravates symptoms of MS patients weighing more than 40 kg; beginning 60 days prior to screening for exclusion criteria: If there is any a severe reaction to caffeine; if you see any progress in disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The ability to walk and balance. Timepoint: Before intervention, 2, 4, 8 and 12 weeks after intervention. Method of measurement: Based on the results of the Kurtzke Expanded Disability Status Scale (EDSS), Twelve Item MS Walking Scale (MSWS-12), Patients' Global Impression of Change (PGIC), The Timed Up and Go (TUG) Test, Berg Balance SCALE (BBS) , Multiple Sclerosis Impact Scale (MSIS-29).	—

Secondary

Measure	Time frame
Drug Side Effects. Timepoint: If any discomfort in the patient of all time trials. Method of measurement: Registered on the basis of safety and tolerability based on AEs (see side effects) and SAEs (serious adverse events observed) and vital signs and electrocardiogram.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactdr.hamed amirifard

zahedan University of Medical Sciences

dr.amirifard@gmail.com+98 54 1341 6708

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026